Research Summary

Dr. Cooperberg has a long experience in prostate cancer clinical and outcomes research, with specific areas of interest including early detection, risk assessment, biomarker validation, health services research, oncologic and health-related quality of life outcomes, comparative effectiveness, and disparities research. He has an extensive research history with CaPSURE and other registry and our institutional databases and tissue bank. He has a strong research interest in prostate cancer risk assessment, and led development and validation of the UCSF Cancer of the Prostate Risk Assessment (CAPRA) pre- and post-operative scores, as well as validation multiple tissue-based genomic markers now in wide clinical use.

From 2013 to 2020 he served as Associate Editor for European Urology, the leading peer-reviewed journal in urology, and as of 2023 am Associate Editor for the Journal of the National Cancer Institute. He also served as the physician lead on the American Urological Association’s new AUA Quality (AQUA) national disease registry with goals of documentation practice patterns, quality of care, and outcomes for patients across the nation with urologic diseases. In 2015, Cooperberg won the AUA Gold Cystoscope Award, awarded annually to one urologist based on contributions to the field within the first ten years of practice.

He has a longstanding interest in the development and validation of prostate cancer imaging tests and other biomarkers for prognostic risk, and led the pivotal validation studies for two of the three commercial tissue tests currently on the market for newly diagnosed prostate cancer. He has been PI on an R01 investigating miRNA as a noninvasive risk stratification tool for prostate cancer, and will soon start new one looking examining the black box of pathology artificial intelligence algorithms through the lens of spatial multi-omics. He serves as Urology co-Leader for the UCSF Helen Diller Family Comprehensive Cancer Center Prostate Program and is also Chief of Urology at the San Francisco VA Medical Center.

Research Funding

  • August 10, 2016 - July 31, 2021 - Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA198145
  • August 8, 2012 - May 31, 2017 - Prospective validation of a multi-marker prostate cancer prediction model , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA160816

Education

Dartmouth College, Hanover, NH, BA, 1991-95, English
Yale University, New Haven, CT, MD, MPH, 1995-00, Medicine, Health Policy

Honors & Awards

  • 1995
    College honors: summa cum laude, Phi Beta Kappa, high honors in major, Presidential Scholar, Rufus Choate Scholar, B. William Hochman Prize in American Literature
  • 1996
    American Cancer Society Research Fellowship
  • 1999
    AMA John Conley Ethics Essay Contest, honorable mention
  • 2003
    UCSF Prostate Cancer Research Symposium, 2nd place, Clinical Research
  • 2004
    UCSF Prostate, Breast, Prostate SPORE Scientific Retreat, honorable mention, Clinical Research
  • 2005
    Northern California Urology Resident Research Symposium, 1st place, Clinical Research
  • 2006
    Northern California Urology Resident Research Symposium, 3rd place, Clinical Research
  • 2007
    AUA Gerald P. Murphy Prostate Scholar
  • 2007
    Northern California Urology Resident Research Symposium, 2nd place, Clinical Research
  • 2007
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Society of Urologic Oncology Poster Session, 3rd place overall
  • 2008
    Western Section AUA Miley B. Wesson Resident Essay Contest, 3rd place
  • 2008
    Western Section AUA Poster Session I, 1st place
  • 2017
    2016 physician award, Marin Prostate Cancer Information and Support Group

Selected Publications

  1. Cooperberg MR. Re: Artificial Intelligence and Radiologists in Prostate Cancer Detection on MRI (PI-CAI): An International, Paired, Non-inferiority, Confirmatory Study. Eur Urol. 2024 Nov 21.  View on PubMed
  2. Ajjawi I, Loeb S, Cooperberg MR, Catalona WJ, Gross CP, Ma X, Leapman MS. Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020. JAMA. 2024 Nov 20.  View on PubMed
  3. Zhao Y, Gulati R, Yang Z, Newcomb L, Zheng Y, Zhu K, Liu M, Heijnsdijk EAM, Haffner MC, Cooperberg M, Eggener SE, De Marzo AM, Kibel AS, Rizopoulos D, Hall IJ, Etzioni R. Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling. J Natl Cancer Inst. 2024 Nov 20.  View on PubMed
  4. Washington SL, Fakunle M, Wang L, Braun AE, Leapman M, Cowan JE, Cooperberg MR. County-level racial disparities in prostate cancer specific mortality from 2005 to 2020. JNCI Cancer Spectr. 2024 Nov 04.  View on PubMed
  5. Nik-Ahd F, Anger JT, Cooperberg MR, Freedland SJ. Prostate cancer in transgender women - challenges in research and clinical care. Nat Rev Urol. 2024 Nov 04.  View on PubMed
  6. Gaylis FD, Leapman MS, Ellis SD, Hu S, Cooperberg MR, Loeb S, Chen RC, Cohen ES, Dato PE, Aynehchi S, David R, Topp R, Santomauro B, Ginsburg K, Catalona WJ. Feasibility of Pay for Performance and Transparency Interventions on the Selection and Quality of Observational Management for Patients with Low-Risk Prostate Cancer in the Community Practice. Urol Pract. 2024 Oct 25; 101097UPJ0000000000000745.  View on PubMed
  7. Patel SA, Patil D, Smith J, Saigal CS, Litwin MS, Hu JC, Cooperberg MR, Carroll PR, Klein EA, Kibel AS, Andriole GL, Han M, Michalski JM, Wood DP, Hembroff LA, Spratt DE, Wei JT, Sandler HM, Hamstra DA, Pisters L, Kuban D, Regan MM, Wagner A, Crociani CM, Kaplan I, Sanda MG, Chang P, PROST-QA/RP2 Consortium. Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA Netw Open. 2024 Oct 01; 7(10):e2440747.  View on PubMed
  8. Cooperberg MR, Braun AE, Berlin A, Kibel AS, Eggener SE, CANCER-GG1 Writing Group
    . When is prostate cancer really cancer? J Natl Cancer Inst. 2024 Oct 01.  View on PubMed
  9. Shee K, Nie J, Cowan JE, Wang L, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance. Eur Urol Oncol. 2024 Sep 27.  View on PubMed
  10. Patel HV, Breyer BN, Jones C, Mbassa R, Meeks W, Fang R, Cooperberg MR. Contemporary Trends of Benign Prostatic Hyperplasia Procedures in the AUA Quality Registry: Are We Moving the Needle Toward More Minimally Invasive Treatments? Urol Pract. 2024 Aug 21; 101097UPJ0000000000000691.  View on PubMed
  11. Deivasigamani S, Adams ES, Stock S, Kotamarti S, Séguier D, Taha T, Howard LE, Aminsharifi A, Jibara G, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Klaassen Z, Guerrios-Rivera L, Freedland SJ, Polascik TJ. Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study. Prostate Cancer Prostatic Dis. 2024 Aug 12.  View on PubMed
  12. Leapman MS, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Sprenkle PC, Ross AE. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. Eur Urol Oncol. 2024 Aug 03.  View on PubMed
  13. Kohlbrenner R, Wu X, Nguyen HG, Cooperberg MR, Chakravarty T, Carroll PR, Hope TA. Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. Radiology. 2024 08; 312(2):e232544.  View on PubMed
  14. Nik-Ahd F, De Hoedt AM, Butler C, Anger JT, Carroll PR, Cooperberg MR, Freedland SJ. Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen. JAMA. 2024 07 23; 332(4):335-337.  View on PubMed
  15. Sundaresan VM, Wang R, Long JB, Sprenkle PC, Seibert TM, Loeb S, Cooperberg MR, Catalona WJ, Ma X, Gross CP, Leapman MS. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urol Pract. 2024 Nov; 11(6):965-973.  View on PubMed
  16. Cooperberg MR. PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance. Eur Urol. 2024 Sep; 86(3):256-257.  View on PubMed
  17. Leapman MS, Ho J, Liu Y, Filson CP, Zhao X, Hakansson A, Proudfoot JA, Davicioni E, Martin DT, An Y, Seibert TM, Lin DW, Spratt DE, Cooperberg MR, Ross AE, Sprenkle PC. Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage. JAMA Netw Open. 2024 Jun 03; 7(6):e2417274.  View on PubMed
  18. Nguyen JK, Harik LR, Klein EA, Li J, Corrigan D, Liu S, Chan E, Hawley S, Auman H, Newcomb LF, Carroll PR, Cooperberg MR, Filson CP, Simko JP, Nelson PS, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Weight CJ, Lin DW, Brooks JD, McKenney JK. Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage. Histopathology. 2024 Oct; 85(4):598-613.  View on PubMed
  19. Greenland NY, Cooperberg MR, Carroll PR, Cowan JE, Simko JP, Stohr BA, Chan E. Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. Prostate. 2024 Aug; 84(11):1076-1085.  View on PubMed
  20. Crawford ED, Bryce AH, Hussain MH, Agarwal N, Beltran H, Cooperberg MR, Petrylak DP, Shore N, Spratt DE, Tagawa ST, Antonarakis ES, Aparicio AM, Armstrong AJ, Boike TP, Calais J, Carducci MA, Chapin BF, Cookson MS, Davis JW, Dorff T, Eggener SE, Feng FY, Gleave M, Higano C, Iagaru A, Morgans AK, Morris M, Murray KS, Poage W, Rettig MB, Sartor O, Scher HI, Sieber P, Small E, Srinivas S, Yu EY, Zhang T, Koo PJ. Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1. JU Open Plus. 2024 Apr; 2(4).  View on PubMed

Go to UCSF Profiles, powered by CTSI